Hospital For Special Surgery
- Type
- Teaching hospital
- Where
- New York, NY
- Medicare CCN
- 330270
- Received
- $6,238,951 in 389 records, 2020 ($3,891,735 general, $2,347,215 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Patent assignee: Hospital for Special Surgery Fuzzy (name and state)
- Trademark owner: Hospital for Special Surgery Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 204 | $3,891,735 |
| 2020 | Research payment | 185 | $2,347,215 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 185 | $2,347,215 |
| Space rental or facility fees (teaching hospital only) | 55 | $1,773,925 |
| Royalty or License | 18 | $999,699 |
| Grant | 75 | $829,514 |
| Consulting Fee | 5 | $146,106 |
| Gift | 15 | $86,087 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 33 | $47,845 |
| Education | 2 | $8,199 |
| Charitable Contribution | 1 | $357 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Globus Medical, Inc. | $15,417 | Grant | Cash or cash equivalent | Device, Spine | 2020 | |
| 2020-12-31 | Stryker Corporation | $14,662 | Gift | In-kind items and services | CROSSFIRE 2 INTEGRATED RESECTION & ENERGY SYSTEM Device, ARTHROSCOPY | 2020 | |
| 2020-12-31 | Stryker Corporation | $14,662 | Gift | In-kind items and services | CROSSFIRE 2 INTEGRATED RESECTION & ENERGY SYSTEM Device, ARTHROSCOPY | 2020 | |
| 2020-12-31 | Stryker Corporation | $13,779 | Gift | In-kind items and services | CROSSFLOW PUMP Device, ARTHROSCOPY | 2020 | |
| 2020-12-31 | Stryker Corporation | $13,779 | Gift | In-kind items and services | CROSSFLOW PUMP Device, ARTHROSCOPY | 2020 | |
| 2020-12-31 | AstraZeneca UK Limited | $7,597 | Research payment | In-kind items and services | The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre R | 2020 | |
| 2020-12-31 | Stryker Corporation | $7,576 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Stryker Corporation | $1,520 | Gift | In-kind items and services | CROSSFIRE FOOTSWITCH Device, SPORTS MEDICINE | 2020 | |
| 2020-12-31 | Stryker Corporation | $1,520 | Gift | In-kind items and services | CROSSFIRE FOOTSWITCH Device, SPORTS MEDICINE | 2020 | |
| 2020-12-31 | Abbott Laboratories | $315 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-12-31 | Stryker Corporation | $0 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-29 | PFIZER INC. | $250,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-23 | GE HEALTHCARE | $600,071 | Research payment | Cash or cash equivalent | Device, MAGNETIC RESONANCE | DEVELOPMENT OF TECHNOLOGY TO EXTEND SCOPE OF MRI | 2020 |
| 2020-12-22 | Medical Device Business Services, Inc. | $5,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-22 | Stryker Corporation | $1,500 | Research payment | Cash or cash equivalent | TRIDENT Device, HIPS | METAL ION LEVELS IN STRYKER TRIDENT II TRITANIUM SYSTEM WITH MDM LINER, CERAMIC HEAD, AND ACCOLADE II OR SECURFIT ADVANC | 2020 |
| 2020-12-17 | Alexion Pharmaceuticals, Inc. | $6,910 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-12-17 | Smith+Nephew, Inc. | $606 | Research payment | Cash or cash equivalent | OXINIUM Hip Device, Recon Hips | A Multi-Center, Randomized Controlled Study of Efficacy and Safety of the OXINIUM DH Total Hip Replacement System in Sub | 2020 |
| 2020-12-16 | Stryker Corporation | $30,895 | Research payment | Cash or cash equivalent | MAKO Device, KNEES, HIPS | MULTICENTER STUDY FOR ROBOTIC-ARM ASSISTED THA 4.0 SYSTEM WITH INTEGRATION OF PELVIC TILT AND ROM ASSESSMENTS: IMPLANT P | 2020 |
| 2020-12-15 | Orthofix Medical, Inc. | $4,304 | Research payment | Cash or cash equivalent | M6-C Artificial Cervical Disc Device, Prosthesis, Intervertebral Disc | M6-C IDE | 2020 |
| 2020-12-15 | Ortho Development Corporation | $1,907 | Royalty or License | Cash or cash equivalent | Spinal Rod Device, ORTHOPEDIC DEVICE | 2020 | |
| 2020-12-14 | EXACTECH, INC. | $5,422 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VANTAGE Device, ORTHOPAEDIC | 2020 | |
| 2020-12-14 | UCB SA | $22 | Research payment | In-kind items and services | A RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU | 2020 | |
| 2020-12-11 | Aesculap Implant Systems, LLC | $3,774 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-11 | Aesculap Implant Systems, LLC | $2,440 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-11 | KCI USA, Inc. | $1,750 | Research payment | Cash or cash equivalent | PREVENA Device, NON-COVERED | Closed Incision Negative Pressure Therapy Versus Standard of Care Surgical Dressing in Revision Total Knee Arthroplasty | 2020 |
| 2020-12-10 | Aesculap, Inc. | $12,314 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Orthofix Medical, Inc. | $2,869 | Research payment | Cash or cash equivalent | M6-C Artificial Cervical Disc Device, Prosthesis, Intervertebral Disc | M6-C IDE | 2020 |
| 2020-12-10 | Abbott Laboratories | $746 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Stryker Corporation | $19,067 | Research payment | Cash or cash equivalent | TRIDENT Device, HIPS | METAL ION LEVELS IN STRYKER TRIDENT II TRITANIUM SYSTEM WITH MDM LINER, CERAMIC HEAD, AND ACCOLADE II OR SECURFIT ADVANC | 2020 |
| 2020-12-09 | ACUMED LLC | $2,275 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $2,275 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $1,743 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | Stryker Corporation | $1,475 | Research payment | Cash or cash equivalent | RESTORATION Device, HIPS | RESTORATION; ANATOMIC DUAL MOBILITY (ADM) X3; ACETABULAR SYSTEM STUDY WITH LONG TERM DATA COLLECTION FOR THE ACCOLADE; I | 2020 |
| 2020-12-09 | ACUMED LLC | $955 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $955 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $925 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $360 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-09 | ACUMED LLC | $180 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Foot & Ankle | 2020 | |
| 2020-12-08 | Alexion Pharmaceuticals, Inc. | $6,680 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-12-08 | Smith+Nephew, Inc. | $4,914 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMBIENT HIPVAC Device, Sports Med Hip | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $4,186 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $4,186 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JOURNEY II Device, Recon Knees | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $4,185 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | WEREWOLF Device, Sports Med Resection | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $3,678 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $3,623 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Q-FIX Shoulder Device, Sports Med Shoulder | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $3,508 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACUFEX Device, Sports Med Knee | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $2,122 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JOURNEY II Device, Recon Knees | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $799 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AMBIENT HIPVAC Device, Sports Med Hip | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $799 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Q-FIX Shoulder Device, Sports Med Shoulder | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $705 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ACUFEX Device, Sports Med Knee | 2020 | |
| 2020-12-08 | Smith+Nephew, Inc. | $525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | WEREWOLF Device, Sports Med Resection | 2020 | |
| 2020-12-03 | Smith+Nephew, Inc. | $13,096 | Research payment | In-kind items and services | OXINIUM Hip Device, Recon Hips | 2020 | |
| 2020-12-03 | EXACTECH, INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NOVATION HIP Device, ORTHOPAEDIC | 2020 | |
| 2020-12-02 | Stryker Corporation | $12,710 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | MAVRIC MRI USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIDENT II TRITANIUM SYSTEM | 2020 |
| 2020-12-02 | Smith+Nephew, Inc. | $1,653 | Research payment | Cash or cash equivalent | BIRMINGHAM HIP Device, Recon Hips | A Post-Approval Study of the Birmingham Hip Resurfacing (BHR) Radiological System Review | 2020 |
| 2020-12-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $63 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2020 |
| 2020-11-24 | Alexion Pharmaceuticals, Inc. | $4,996 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-11-20 | Smith+Nephew, Inc. | $2,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-20 | Smith+Nephew, Inc. | $2,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-20 | Smith+Nephew, Inc. | $2,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-20 | Smith+Nephew, Inc. | $2,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-19 | CSL Behring | $2,965 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $1,428 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $1,342 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $1,045 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $963 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $632 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $408 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $365 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $261 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $62 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-19 | CSL Behring | $18 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-18 | Medtronic USA, Inc. | $7,376 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CD HORIZON Device, TL | 2020 | |
| 2020-11-18 | Zimmer Biomet Holdings, Inc. | $3,000 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-11-17 | AstraZeneca Pharmaceuticals LP | $13,900 | Research payment | Cash or cash equivalent | FASENRA Drug, Respiratory | A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Sa | 2020 |
| 2020-11-17 | Medical Device Business Services, Inc. | $5,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-17 | Medical Device Business Services, Inc. | $3,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-17 | Smith+Nephew, Inc. | $606 | Research payment | Cash or cash equivalent | OXINIUM Hip Device, Recon Hips | A Multi-Center, Randomized Controlled Study of Efficacy and Safety of the OXINIUM DH Total Hip Replacement System in Sub | 2020 |
| 2020-11-17 | GE HEALTHCARE | $357 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-11-16 | Medtronic USA, Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-11-12 | Radius Health, Inc. | $90,113 | Research payment | Cash or cash equivalent | Phase II Trial of Abaloparatide vs Placebo - Spinal Fusion - Phase II Trial of Abaloparatide vs Placebo in Post-Menopaus | 2020 | |
| 2020-11-11 | Ortho Development Corporation | $419 | Royalty or License | Cash or cash equivalent | Spinal Rod Device, ORTHOPEDIC DEVICE | 2020 | |
| 2020-11-10 | Orion Corporation | $2,778 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-11-09 | Takeda Pharmaceuticals U.S.A., Inc. | $250 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-11-06 | Smith+Nephew, Inc. | $572 | Research payment | Cash or cash equivalent | OXINIUM Hip Device, Recon Hips | A Multi-Center, Randomized Controlled Study of Efficacy and Safety of the OXINIUM DH Total Hip Replacement System in Sub | 2020 |
| 2020-11-05 | Smith+Nephew, Inc. | $5,650 | Research payment | Cash or cash equivalent | OR3O Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2020 |
| 2020-11-05 | Alexion Pharmaceuticals, Inc. | $2,498 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-11-05 | Amgen Inc. | $1,882 | Research payment | In-kind items and services | Enbrel Biological, Inflammation | Enbrel RA Remission Study | 2020 |
| 2020-11-04 | Stryker Corporation | $7,747 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIDENT II TRITANIUM OUTCOMES STUDY | 2020 |
| 2020-11-04 | TREACE MEDICAL CONCEPTS, INC. | $5,628 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lapiplasty System Device, Y | 2020 | |
| 2020-11-04 | Stryker Corporation | $1,793 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIDENT II TRITANIUM OUTCOMES STUDY | 2020 |
| 2020-11-04 | Stryker Corporation | $1,597 | Research payment | Cash or cash equivalent | RESTORATION Device, HIPS | RESTORATION; ANATOMIC DUAL MOBILITY (ADM) X3; ACETABULAR SYSTEM STUDY WITH LONG TERM DATA COLLECTION FOR THE ACCOLADE; I | 2020 |
| 2020-11-04 | Stryker Corporation | $765 | Research payment | Cash or cash equivalent | SECUR-FIT Device, HIPS | SECURFIT ADVANCED OUTCOMES STUDY | 2020 |
| 2020-11-04 | Stryker Corporation | $162 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIDENT II TRITANIUM OUTCOMES STUDY | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $10,000 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $2,900 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-11-03 | Takeda Pharmaceuticals U.S.A., Inc. | $54 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2020 |
| 2020-11-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $62 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2020 |
| 2020-10-30 | EXACTECH, INC. | $2,500 | Grant | Cash or cash equivalent | NOVATION HIP Device, ORTHOPAEDIC | 2020 | |
| 2020-10-28 | Smith+Nephew, Inc. | $121,249 | Research payment | Cash or cash equivalent | Smith and Nephew Clinical Data Registry | 2020 | |
| 2020-10-22 | Orthofix Medical, Inc. | $11,650 | Research payment | Cash or cash equivalent | M6-C Artificial Cervical Disc Device, Prosthesis, Intervertebral Disc | M6-C IDE | 2020 |
| 2020-10-22 | Zimmer Biomet Holdings, Inc. | $5,000 | Grant | Cash or cash equivalent | Spine-None Device, Spine | 2020 | |
| 2020-10-20 | Smith+Nephew, Inc. | $12,792 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VISIONAIRE Device, Recon Knees | 2020 | |
| 2020-10-20 | Smith+Nephew, Inc. | $9,921 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VISIONAIRE Device, Recon Knees | 2020 | |
| 2020-10-20 | CSL Behring | $6,000 | Research payment | Cash or cash equivalent | Privigen Biological, Immunology | A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro1 | 2020 |
| 2020-10-20 | CSL Behring | $4,000 | Research payment | Cash or cash equivalent | Privigen Biological, Immunology | A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro1 | 2020 |
| 2020-10-20 | CSL Behring | $2,900 | Research payment | Cash or cash equivalent | Privigen Biological, Immunology | A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro1 | 2020 |
| 2020-10-20 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | Privigen Biological, Immunology | A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro1 | 2020 |
| 2020-10-15 | Alexion Pharmaceuticals, Inc. | $2,425 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-10-15 | Ortho Development Corporation | $911 | Royalty or License | Cash or cash equivalent | Spinal Rod Device, ORTHOPEDIC DEVICE | 2020 | |
| 2020-10-15 | Ortho Development Corporation | $72 | Royalty or License | Cash or cash equivalent | ISS Device, ORTHOPEDIC DEVICE | 2020 | |
| 2020-10-09 | Smith+Nephew, Inc. | $13,096 | Research payment | In-kind items and services | OXINIUM Hip Device, Recon Hips | 2020 | |
| 2020-10-09 | Synthes GmbH | $6,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-10-08 | Zimmer Biomet Holdings, Inc. | $5,000 | Grant | Cash or cash equivalent | Spine-None Device, Spine | 2020 | |
| 2020-10-07 | Stryker Corporation | $10,016 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | MAVRIC MRI USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIDENT II TRITANIUM SYSTEM | 2020 |
| 2020-10-07 | Stryker Corporation | $1,500 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | MAVRIC MRI USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIDENT II TRITANIUM SYSTEM | 2020 |
| 2020-10-07 | Stryker Corporation | $1,500 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2020 |
| 2020-10-06 | Smith+Nephew, Inc. | $23,550 | Research payment | Cash or cash equivalent | OXINIUM Hip Device, Recon Hips | A Multi-Center, Randomized Controlled Study of Efficacy and Safety of the OXINIUM DH Total Hip Replacement System in Sub | 2020 |
| 2020-10-06 | Abbott Laboratories | $798 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-10-06 | Abbott Laboratories | $111 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-10-05 | Synthes GmbH | $32,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-10-05 | Synthes GmbH | $6,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-10-05 | Smith+Nephew, Inc. | $607 | Research payment | Cash or cash equivalent | BIRMINGHAM HIP Device, Recon Hips | A Post-Approval Study of the Birmingham Hip Resurfacing (BHR) Radiological System Review | 2020 |
| 2020-10-05 | UOC USA INC | $275 | Consulting Fee | Cash or cash equivalent | U-Motion II, UTF Device, UOC Hip System | 2020 | |
| 2020-10-01 | Limacorporate S.p.A. | $100,000 | Consulting Fee | Cash or cash equivalent | Product Portfolio Device, Devices | 2020 | |
| 2020-10-01 | GE HEALTHCARE | $699 | Education | Cash or cash equivalent | 2020 | ||
| 2020-10-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $62 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2020 |
| 2020-09-30 | EXACTECH, INC. | $362,526 | Royalty or License | Cash or cash equivalent | OPTETRAK Device, ORTHOPAEDIC | 2020 | |
| 2020-09-30 | EXACTECH, INC. | $18,825 | Research payment | Cash or cash equivalent | OPTETRAK Device, ORTHOPAEDIC | 2020 | |
| 2020-09-29 | UCB SA | $12,400 | Research payment | Cash or cash equivalent | Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan | 2020 | |
| 2020-09-19 | EXACTECH, INC. | $5,188 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VANTAGE Device, ORTHOPAEDIC | 2020 | |
| 2020-09-15 | Ortho Development Corporation | $2,254 | Royalty or License | Cash or cash equivalent | Spinal Rod Device, ORTHOPEDIC DEVICE | 2020 | |
| 2020-09-14 | Smith+Nephew, Inc. | $5,265 | Research payment | Cash or cash equivalent | BIRMINGHAM HIP Device, Recon Hips | A Post-Approval Study of the Birmingham Hip Resurfacing (BHR) Radiological System Review | 2020 |
| 2020-09-14 | Orthofix Medical, Inc. | $1,434 | Research payment | Cash or cash equivalent | M6-C Artificial Cervical Disc Device, Prosthesis, Intervertebral Disc | M6-C IDE | 2020 |
| 2020-09-11 | Amgen Inc. | $3,738 | Research payment | In-kind items and services | Phase 2b SLE Dose-Finding | 2020 | |
| 2020-09-10 | Medtronic USA, Inc. | $10,763 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CD HORIZON Device, TL | 2020 | |
| 2020-09-10 | Smith+Nephew, Inc. | $750 | Research payment | Cash or cash equivalent | OR3O Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2020 |
| 2020-09-10 | Smith+Nephew, Inc. | $750 | Research payment | Cash or cash equivalent | OR3O Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2020 |
| 2020-09-10 | Smith+Nephew, Inc. | $750 | Research payment | Cash or cash equivalent | OR3O Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2020 |
| 2020-09-10 | Smith+Nephew, Inc. | $750 | Research payment | Cash or cash equivalent | OR3O Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2020 |
| 2020-09-09 | Stryker Corporation | $300 | Research payment | Cash or cash equivalent | RESTORATION Device, HIPS | RESTORATION; ANATOMIC DUAL MOBILITY (ADM) X3; ACETABULAR SYSTEM STUDY WITH LONG TERM DATA COLLECTION FOR THE ACCOLADE; I | 2020 |
| 2020-09-09 | Orion Corporation | $90 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-09-03 | Teva Pharmaceuticals USA, Inc. | $5,643 | Research payment | Cash or cash equivalent | AJOVY Biological, Central Nervous System | A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including | 2020 |
| 2020-09-03 | Novartis Pharmaceuticals Corporation | $815 | Research payment | Cash or cash equivalent | VAY736 Biological | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER PHASE 2 DOSE RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF | 2020 |
| 2020-09-03 | Teva Pharmaceuticals USA, Inc. | $450 | Research payment | Cash or cash equivalent | AJOVY Biological, Central Nervous System | A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including | 2020 |
| 2020-09-03 | Teva Pharmaceuticals USA, Inc. | $300 | Research payment | Cash or cash equivalent | AJOVY Biological, Central Nervous System | A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including | 2020 |
| 2020-09-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | $60 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2020 |
| 2020-08-31 | EXACTECH, INC. | $233,684 | Royalty or License | Cash or cash equivalent | NOVATION HIP Device, ORTHOPAEDIC | 2020 | |
| 2020-08-31 | EXACTECH, INC. | $6,096 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VANTAGE Device, ORTHOPAEDIC | 2020 | |
| 2020-08-26 | Teva Pharmaceuticals USA, Inc. | $2,406 | Research payment | Cash or cash equivalent | AJOVY Biological, Central Nervous System | A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including | 2020 |
| 2020-08-26 | Smith+Nephew, Inc. | $877 | Research payment | Cash or cash equivalent | OXINIUM Hip Device, Recon Hips | A Multi-Center, Randomized Controlled Study of Efficacy and Safety of the OXINIUM DH Total Hip Replacement System in Sub | 2020 |
| 2020-08-26 | Boehringer Ingelheim Pharma GmbH & Co.KG | $158 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2020 |
| 2020-08-25 | Smith+Nephew, Inc. | $270 | Research payment | Cash or cash equivalent | OXINIUM Hip Device, Recon Hips | A Multi-Center, Randomized Controlled Study of Efficacy and Safety of the OXINIUM DH Total Hip Replacement System in Sub | 2020 |
| 2020-08-20 | Smith+Nephew, Inc. | $4,320 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-08-20 | Smith+Nephew, Inc. | $3,776 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-08-20 | Smith+Nephew, Inc. | $3,568 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-08-20 | Smith+Nephew, Inc. | $3,278 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-08-20 | Smith+Nephew, Inc. | $955 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-08-20 | Smith+Nephew, Inc. | $798 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-08-20 | Smith+Nephew, Inc. | $477 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-08-20 | Smith+Nephew, Inc. | $320 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LENS Device, Sports Med Visualization | 2020 | |
| 2020-08-20 | Teva Pharmaceuticals USA, Inc. | $300 | Research payment | Cash or cash equivalent | AJOVY Biological, Central Nervous System | A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including | 2020 |
| 2020-08-20 | Teva Pharmaceuticals USA, Inc. | $200 | Research payment | Cash or cash equivalent | AJOVY Biological, Central Nervous System | A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including | 2020 |
| 2020-08-19 | Abbott Laboratories | $244 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-19 | Abbott Laboratories | $229 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-18 | Smith+Nephew, Inc. | $15,330 | Research payment | Cash or cash equivalent | OXINIUM Hip Device, Recon Hips | A Multi-Center, Randomized Controlled Study of Efficacy and Safety of the OXINIUM DH Total Hip Replacement System in Sub | 2020 |
| 2020-08-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Extension | 2020 |
| 2020-08-15 | Medical Device Business Services, Inc. | $1,836 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-15 | Zimmer Biomet Holdings, Inc. | $1,750 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-15 | Zimmer Biomet Holdings, Inc. | $1,256 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-15 | Medical Device Business Services, Inc. | $953 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-15 | Medical Device Business Services, Inc. | $896 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-15 | Zimmer Biomet Holdings, Inc. | $745 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-15 | Zimmer Biomet Holdings, Inc. | $727 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-15 | Zimmer Biomet Holdings, Inc. | $721 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-15 | Medical Device Business Services, Inc. | $697 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-15 | Medical Device Business Services, Inc. | $685 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-15 | Zimmer Biomet Holdings, Inc. | $631 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-15 | Zimmer Biomet Holdings, Inc. | $602 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-15 | Zimmer Biomet Holdings, Inc. | $446 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-15 | Medical Device Business Services, Inc. | $378 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-15 | Medical Device Business Services, Inc. | $372 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-15 | Zimmer Biomet Holdings, Inc. | $185 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-08-14 | Regeneron Pharmaceuticals, Inc. | $22,217 | Research payment | Cash or cash equivalent | STUDY TO EVALUATE ARTHROPLASTY SPECIMENS IN THE PHASE 3 FASINUMAB PROGRAM FOR OSTEOARTHRITIS OF THE KNEE AND HIP | 2020 | |
| 2020-08-14 | Regeneron Pharmaceuticals, Inc. | $1,462 | Research payment | Cash or cash equivalent | STUDY TO EVALUATE ARTHROPLASTY SPECIMENS IN THE PHASE 3 FASINUMAB PROGRAM FOR OSTEOARTHRITIS OF THE KNEE AND HIP | 2020 | |
| 2020-08-14 | Ortho Development Corporation | $727 | Royalty or License | Cash or cash equivalent | Spinal Rod Device, ORTHOPEDIC DEVICE | 2020 | |
| 2020-08-12 | Smith+Nephew, Inc. | $121,249 | Research payment | Cash or cash equivalent | JOURNEY II BCS Device, Recon Knees | Smith and Nephew Clinical Data Registry | 2020 |
| 2020-08-12 | GE HEALTHCARE | $42,000 | Research payment | Cash or cash equivalent | SERIAL ULTRASONOGRAPHY FOR THE ASSESSMENT OF HEALING AND TIMING OF RETURN-TO-PLAY IN ATHLETES WITH LOWER EXTREMITY BONE | 2020 | |
| 2020-08-12 | Stryker Corporation | $875 | Research payment | Cash or cash equivalent | REJUVENATE Device, HIPS | CLINICAL AND RADIOGRAPHIC OUTCOME OF THE STRYKER REJUVENATE MODULAR STEMS | 2020 |
| 2020-08-11 | Orion Corporation | $12,980 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES) | 2020 | |
| 2020-08-10 | Lima USA, Inc. | $342,482 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Promade Device, Devices | 2020 | |
| 2020-08-07 | Stryker Corporation | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-08-07 | Smith+Nephew, Inc. | $4,528 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PERI-LOC PFP Device, Trauma Plates, Screws, and Nails | 2020 | |
| 2020-08-07 | Smith+Nephew, Inc. | $2,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PERI-LOC PFP Device, Trauma Plates, Screws, and Nails | 2020 | |
| 2020-08-07 | Smith+Nephew, Inc. | $1,520 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PERI-LOC PFP Device, Trauma Plates, Screws, and Nails | 2020 |
The latest 200 records of 389.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New York, NY, county Kings County, NY, state New York; placed by its city name.
| Measure | Place (city or town) New York, NY | County Kings County, NY | State New York |
|---|---|---|---|
| Population B01003 | 8,483,844 | 2,631,580 | 19,852,366 |
| Population, 2020 census P1 | 8,804,190 | 2,736,074 | 20,201,249 |
| Median age B01002 | 38.2 | 36.5 | 39.8 |
| Under 18 B01001 | 20.2% | 22.2% | 20.5% |
| 65 and over B01001 | 16.6% | 15.5% | 17.9% |
| Households B11001 | 3,334,088 | 1,009,927 | 7,722,646 |
| Foreign born B05002 | 36.6% | 35.3% | 22.8% |
| Median household income B19013 | $80,483 | $80,263 | $85,974 |
| Median family income B19113 | $91,707 | $88,947 | $106,873 |
| Per capita income B19301 | $51,844 | $47,575 | $50,712 |
| Poverty rate B17001 | 17.9% | 19.1% | 14.0% |
| Unemployment rate B23025 | 8.0% | 7.9% | 6.4% |
| Civilian labor force B23025 | 4,392,297 | 1,353,361 | 10,171,766 |
| Mean commute (minutes) B08013 | 40.3 | 41.7 | 32.6 |
| Bachelor's degree or higher B15003 | 41.6% | 42.1% | 40.2% |
| Housing units B25001 | 3,678,486 | 1,100,772 | 8,585,241 |
| Owner-occupied B25003 | 32.8% | 29.5% | 54.3% |
| Renters B25003 | 67.2% | 70.5% | 45.7% |
| Median home value B25077 | $777,600 | $905,000 | $423,800 |
| Median gross rent B25064 | $1,821 | $1,833 | $1,621 |
| White, not Hispanic B03002 | 31.0% | 36.1% | 52.8% |
| Black B03002 | 20.4% | 26.6% | 13.4% |
| Hispanic or Latino B03002 | 28.5% | 19.0% | 19.8% |
| Asian B03002 | 14.6% | 12.1% | 9.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New York, NY.
Comments